{Reference Type}: Journal Article
{Title}: Trophinin-associated protein expression correlates with shorter survival of patients with glioma: a study based on multiple data fusion analysis.
{Author}: Sun Y;Liu ZD;Liu RZ;Lian XY;Cheng XB;Jia YL;Liu BF;Gao YZ;Wang X;
{Journal}: Mol Biol Rep
{Volume}: 49
{Issue}: 8
{Year}: Aug 2022
{Factor}: 2.742
{DOI}: 10.1007/s11033-022-07622-8
{Abstract}: <B>BACKGROUND: </B>Trophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of various cancers. However, there is limited information on the role of TROAP in glioma.<BR><B>RESULTS: </B>We obtained clinical information on 1948 patients with glioma from The Cancer Genome Atlas, Gene Expression Omnibus and the Chinese Glioma Genome Atlas. Basal assays were used to measure changes in TROAP expression levels in high-grade glioma cell lines and in normal human astrocytes. Quantitative reverse transcription polymerase chain reaction assays showed that TROAP expression was higher in glioma cell lines than in normal astrocytes. The expression level of TROAP in 749 glioma was significantly higher than that in 228 normal brain tissues using Student's t test. The expression of TROAP has a positive relationship with the clinical characteristics of poor prognosis, such as WHO grade, age and has negatively correlated with the indicators of beneficial prognosis, such as IDH mutation and 1p19q co-deletion. Kaplan-Meier survival curves, single multifactor analysis were used to analyze correlations between TROAP and clinical features and prognosis of gliomas. In addition, TROAP overexpression was an independent risk factor for glioma and was associated with reduced overall survival of patients with glioma particularly in patients with WHO grade III and grade IV glioma. Gene set enrichment analysis showed that homologous recombination, cell cycle, and p53 signaling pathways were enriched in samples overexpressing TROAP.<BR><B>CONCLUSIONS: </B>TROAP is a potential risk factor associated with poor prognosis in patients with glioma and may act as a highly specific biomarker, offering the possibility of individualized glioma treatment.